Lloyd Advisory Services LLC. Invests $230,000 in Sanofi (NASDAQ:SNY)

Lloyd Advisory Services LLC. bought a new stake in Sanofi (NASDAQ:SNY) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,994 shares of the company’s stock, valued at approximately $230,000.

Other institutional investors have also added to or reduced their stakes in the company. Voisard Asset Management Group Inc. purchased a new stake in Sanofi in the fourth quarter worth about $38,000. V Square Quantitative Management LLC bought a new stake in shares of Sanofi during the fourth quarter valued at approximately $490,000. Beacon Financial Group grew its position in Sanofi by 5.6% in the 4th quarter. Beacon Financial Group now owns 15,652 shares of the company’s stock worth $778,000 after purchasing an additional 830 shares during the period. Teachers Retirement System of The State of Kentucky grew its position in Sanofi by 5.5% in the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 199,160 shares of the company’s stock worth $9,904,000 after purchasing an additional 10,400 shares during the period. Finally, Abel Hall LLC bought a new stake in Sanofi in the 4th quarter worth approximately $544,000. Institutional investors own 10.04% of the company’s stock.

Sanofi Trading Up 0.3 %

NASDAQ SNY opened at $54.96 on Friday. The company has a fifty day simple moving average of $55.81 and a two-hundred day simple moving average of $51.33. The stock has a market cap of $139.46 billion, a P/E ratio of 29.87, a P/E/G ratio of 1.57 and a beta of 0.60. Sanofi has a 12-month low of $42.63 and a 12-month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.95 earnings per share. On average, analysts forecast that Sanofi will post 4.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on SNY. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Argus boosted their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Finally, Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Sanofi presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.